Savitz Ryan 4

What Happened Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics (DNTH), was granted a derivative equity award covering 150,000 shares, reported as acquired at $0.00. This was a grant (transaction code A), not a cash purchase or sale, so no immediate proceeds or outlay are reported. The filing shows the award as a derivative interest (stock option/award) rather than an immediate stock transfer.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-04 (appears timely — filed the next business day).
• Reported acquisition: 150,000 shares at $0.00 (derivative equity award).
• Shares owned following the transaction: not specified in the provided excerpt.
• Footnote: the shares underlying the award vest in equal monthly installments over the four years after January 1, 2026, subject to continued service.
• Transaction code: A = Award/Grant.

Context This is a compensation grant that vests over time and does not indicate an immediate sale or market action; vested shares (or options) may require exercise and could be subject to additional restrictions or tax withholding when they vest. Such grants are common for executives and are different from open-market purchases (which some investors view as a stronger bullish signal).